Key result
Non-viral gene delivery shows promise for myocardial repair but faces key systemic barriers.
Why the study?
Conventional therapies for cardiovascular diseases have shown limited therapeutic effects due to a lack of cardiac tissue repair, and the clinical translation of gene therapy depends heavily on delivery technologies.
This review highlights the potential of non-viral gene delivery systems for targeted cardiac cell modulation and tissue repair in myocardial infarction.
Hypothesis-generating for non-viral cardiac gene therapy; prospective studies needed before clinical consideration.
Cardiovascular diseases (CVD) are the leading cause of morbidity and mortality worldwide. Conventional therapies involving surgery or pharmacological strategies have shown limited therapeutic effects due to a lack of cardiac tissue repair. Gene therapy has opened an avenue for the treatment of cardiac diseases through manipulating the underlying gene mechanics. Several gene therapies for cardiac diseases have been assessed in clinical trials, while the clinical translation greatly depends on the delivery technologies. Non-viral vectors are attracting much attention due to their safety and facile production compared to viral vectors. In this review, we discuss the recent progress of non-viral gene therapies for the treatment of cardiovascular diseases, with a particular focus on myocardial infarction (MI). Through a summary of delivery strategies with which to target cardiac tissue and different cardiac cells for MI treatment, this review aims to inspire new insights into the design/exploitation of non-viral delivery systems for gene cargos to promote cardiac repair/regeneration.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2021) conducted a review in Myocardial Infarction. Non-viral gene delivery systems was evaluated. Non-viral gene delivery systems, such as polymers and liposomes, demonstrate promising potential for targeting cardiac tissue and promoting myocardial repair, though clinical translation requires overcoming significant systemic delivery barriers.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: